Biotech CEO: We're Only Growing Stronger With AI, Robotics – The Motley Fool

Founded in 1993 by brothers Tom and David Gardner, The Motley Fool helps millions of people attain financial freedom through our website, podcasts, books, newspaper column, radio show, and premium investing services.
Founded in 1993 by brothers Tom and David Gardner, The Motley Fool helps millions of people attain financial freedom through our website, podcasts, books, newspaper column, radio show, and premium investing services.
You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More
In an interview from Motley Fool Live, recorded on April 8, Fool.com contributor Rachel Warren asks Amyris (AMRS 7.50%) CEO John Melo about how the biotechnology company’s AI and robotics are pushing the boundaries of its innovation and speeding up the time to engineer and design products.

Rachel Warren: We live in an age of digital transformation, and this has been incredibly apparent over the last few years and this has been no exception in the biotech industry, and one thing I find fascinating is how your company is leveraging a variety of tech innovations to create more sustainable and great options across a range of these cases. Can you dive deeper into how tech innovation fits into your product development platforms like AI, for example?
John Melo: Sure. I think the way you framed it, Rachel, is exactly right, which is the further on the edge information technology and AI, artificial intelligence, and data science is pushed, then the better the science of biology and synthetic biology can grow. Because we are dependent on computing power. We’re dependent on data, we’re dependent on better artificial intelligence that enables us to use models to do engineering faster, better, cheaper.
To me, technology as a whole, especially information technology, is the great enabler that actually enables synthetic biology to be all that it can be. How do we use that? Look, we use it across just about everything we do. I think the best example I can give you is we created this AI Scientist. The Scientist is actually an amazing program. We basically give the Scientist a target and the Scientist, using our models and AI, is able to actually engineer an organism to produce our target chemistry faster, better, cheaper than any scientist we have in our system today.
It’s not that the scientist is no longer valid or needed, we obviously need a scientist to use judgment, we need a scientist to assess data, we need a scientist to evolve the models. But the AI Scientist actually is a great workhorse that can do a lot of engineering for us. How does that translate into results? With the amount of AI and programming that we have now and the modeling we’ve done, we could literally go from a target molecule to an organism, making that molecule in fermentation in a month or less for most chemistry.
Now, making it is one thing, you then actually need to be able to make it at a competitive cost so you can commercialize it. That’s in synthetic biology, where the greatest risk and the greatest time consumption is because you have to iterate your way with engineering cycles to be able to get the conversion of that carbon inside of a biological pathway, an organism, to be able to go from carbon and sugarcane to patchouli oil to vanilla, to squalane, to farnesene, whatever that final chemistry is.
Again, we use AI, we use robotics, we use data science, and we use it all at the edge of where the technology is today as a way to enable our speed in engineering and our speed in designing the organism to make the chemistry we want.
*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.
Market-beating stocks from our award-winning service.
Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/13/2022.
Discounted offers are only available to new members. Stock Advisor list price is $199 per year.
Calculated by Time-Weighted Return since 2002. Volatility profiles based on trailing-three-year calculations of the standard deviation of service investment returns.

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool’s premium services.
Making the world smarter, happier, and richer.

Market data powered by Xignite.

source
Connect with Chris Hood, a digital strategist that can help you with AI.

Leave a Reply

Your email address will not be published.

© 2022 AI Caosuo - Proudly powered by theme Octo